Register for our free email digests:
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
With the UK seemingly heading towards an exit from the European Union in just two and a half years’ time, restrictions on the free movement of people, products and finance will impact the life science sector as much as, if not more than, many others.
Denmark, France, Ireland, Italy, Spain and Sweden have all have expressed a keen interest in hosting the European Medicines Agency once the UK leaves the EU. Bids are expected to be made sometime early next year, probably once the UK government triggers Article 50. There is at present no formal process for allocating an agency to a particular EU country, as this tends to be done via a process of political wrangling, so each prospective candidate will need to garner as much support for their bid as possible from the other member states.
Latest From Brexit
A UK Government report is spelling out an achievable vision for the country's life sciences sector which will create an internationally competitive eco-system.
The Medicines Manufacturing Industry Partnership says £140m invested in four centers would provide high-skilled jobs and make the UK the first place in the world where drugs can be discovered, made and packaged.
Ipsen's VP of commercial operations for the UK and Ireland outlines how the French company will use managed access programs to get drugs reimbursed on the NHS and describes Ipsen's plans for growth and greater investment in the UK, despite Brexit uncertainties.
In the spirit of the BIO International Convention's partnering focus, Scrip covered a dealmaker survey and spoke to Bayer about some of its business development priorities on day two of the annual convention. We also report on a payer perspective, post-Brexit EMA rumors and investments in vaccines.
UK industry bodies have expressed concern over the result of the UK general election, as the prime minister decides to form a minority government and EU officials say Brexit talks could be delayed.
The first life sciences-focused specialized investment fund, BioPharma Credit, has completed an IPO in London, lifting the spirits of the investment community pondering the long-term consequences of the country withdrawing from the EU.
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.